Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax

Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax CDK9 inhibitors in cancer research Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update Design, synthesis and anticancer evaluation of selective 2,4-disubstituted pyrimidine CDK9 inhibitors Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents A Novel Pyrazolo[1,5-a]pyrimidine Is a Potent Inhibitor of Cyclin-Dependent Protein Kinases 1, 2, and 9, Which Demonstrates Antitumor Effects in Human Tumor Xenografts Following Oral Administration Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91 Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo